Chonluten 20 mg

PEPTIDE HUBS CHONLUTEN

Peptide Hubs presents Chonluten 20 mg, a specialized synthetic peptide bioregulator derived from lung tissue extracts, designed for advanced pulmonary and respiratory research. This innovative research compound represents a sophisticated tool for investigating respiratory epithelial regeneration, pulmonary homeostasis, and tissue-specific peptide signaling mechanisms. As part of the tissue-specific bioregulator class, Chonluten offers researchers unique insights into organ-targeted peptide regulation, making it valuable for studies exploring lung physiology, respiratory defense mechanisms, and the molecular basis of pulmonary tissue protection and regeneration.

DRUG COMPOSITION

Each 2 mL vial contains 20 mg of high-purity Chonluten in lyophilized form. Chonluten consists of carefully selected short amino acid sequences (typically tripeptides and tetrapeptides) derived from lung tissue-specific protein fragments that have demonstrated biological activity in regulating respiratory function. The exact composition represents proprietary sequences optimized for stability and biological activity. Peptide Hubs' specialized manufacturing process ensures batch-to-batch consistency with purity exceeding 99% as verified by HPLC and mass spectrometry analysis. The formulation contains no additional active ingredients, preservatives, or stabilizers that might interfere with experimental outcomes, allowing researchers to study the compound's specific effects with maximum precision and control.

PHARMACEUTICAL FORM

Chonluten is supplied as a sterile lyophilized powder in a 2 mL amber glass vial sealed with a bromobutyl rubber stopper and aluminum crimp seal. The specialized lyophilization process removes water while maintaining the peptide fragments' structural integrity and biological activity, ensuring long-term stability. The powder appears as a fine white to off-white crystalline substance that should dissolve completely in appropriate sterile solvents such as bacteriostatic water, sterile saline, or physiological buffers. The amber glass provides essential protection against light degradation, which is particularly important for preserving the biological activity of peptide fragments containing photosensitive amino acid residues.

PHARMACEUTICAL GROUP AND ATC CODE

Chonluten belongs to the investigational tissue-specific peptide bioregulator class, specifically targeting respiratory system function and pulmonary tissue homeostasis. While not assigned a formal ATC code for therapeutic use, it falls under investigational agents affecting the respiratory system (potential R category). The compound represents a novel research tool for studying organ-specific peptide regulation, epithelial-mesenchymal interactions, and tissue-protective mechanisms in the respiratory system, with potential applications in pulmonary physiology, toxicology, and regenerative medicine research.

PHARMACOLOGICAL PROPERTIES

Chonluten exerts its research-observed effects through multiple interconnected mechanisms focused on pulmonary tissue homeostasis and respiratory function:

• Epithelial Regeneration Enhancement: Research indicates Chonluten promotes the proliferation and differentiation of respiratory epithelial cells, particularly type II pneumocytes that serve as progenitor cells in alveolar regeneration. Studies suggest the peptide modulates expression of genes involved in epithelial cell cycle regulation, cell adhesion, and differentiation pathways. This epithelial regenerative capacity makes Chonluten valuable for research on lung injury repair, epithelial barrier restoration, and tissue remodeling processes.
• Oxidative Stress Modulation: Chonluten demonstrates significant antioxidant properties specific to pulmonary tissue. Research published in journals like American Journal of Respiratory Cell and Molecular Biology has documented that lung-derived peptides can enhance the expression and activity of pulmonary antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase, while reducing markers of oxidative damage in lung tissue.
• Cytokine Balance Regulation: Chonluten appears to modulate pulmonary inflammatory responses by influencing cytokine production and signaling. Research indicates the peptide can reduce pro-inflammatory cytokine expression (IL-1β, IL-6, TNF-α) while supporting anti-inflammatory mediators, creating a balanced inflammatory environment conducive to tissue repair rather than destructive inflammation.
• Mucociliary Function Support: Preliminary research suggests Chonluten may support mucociliary clearance mechanisms by enhancing ciliary beat frequency and mucus hydration properties, though these effects require further investigation in controlled research settings.
• Gene Expression Modulation: As a tissue-specific bioregulator, Chonluten influences the expression of genes associated with pulmonary development, differentiation, and function. The peptide appears to act through epigenetic mechanisms and transcription factor modulation, potentially restoring youthful gene expression patterns in aging or compromised lung tissue.

THERAPEUTICAL INDICATIONS

FOR RESEARCH USE ONLY. NOT FOR HUMAN CONSUMPTION. In experimental models, Chonluten has been investigated for potential applications in:

1. Pulmonary injury and repair research examining epithelial regeneration and alveolar restoration;
2. Respiratory disease models studying chronic obstructive pulmonary disease (COPD), asthma, and pulmonary fibrosis mechanisms;
3. Lung aging research investigating age-related decline in pulmonary function and regenerative capacity;
4. Oxidative stress studies focusing on pulmonary antioxidant defenses and environmental toxin protection;
5. Respiratory infection models examining host defense mechanisms and tissue resilience;
6. Exercise physiology research investigating respiratory adaptation to training and altitude;
7. Comparative studies of different tissue-specific bioregulators and their organ-specific effects;
8. Toxicology research examining pulmonary protection against environmental insults and pollutants.

DOSES AND METHOD OF ADMINISTRATION

RESEARCH APPLICATIONS ONLY. Experimental protocols vary significantly based on model systems, administration routes, and research objectives. In published rodent studies investigating pulmonary effects, effective doses typically range from 50-200 μg/kg when administered via subcutaneous, intraperitoneal, or intranasal routes. For inhalation studies, researchers typically use nebulized solutions with concentrations of 0.1-1.0 mg/mL. Due to its tissue-specific targeting, researchers may utilize localized administration routes (intratracheal, inhalation) to maximize pulmonary exposure while minimizing systemic effects. The relatively short half-life of peptide fragments (approximately 30-90 minutes) requires consideration of administration frequency in longitudinal studies.

Reconstitution protocol: Using strict aseptic technique, add appropriate volume of sterile bacteriostatic water, physiological saline, or inhalation-grade solvent to the 20 mg vial. For a concentration of 10 mg/mL (ideal for precise dosing in animal studies), add 2 mL of solvent. For 5 mg/mL, add 4 mL. Gently swirl the vial until the powder completely dissolves into a clear, colorless solution. For inhalation studies, additional filtration through 0.22 μm filters may be recommended. For research requiring repeated administration, aliquot reconstituted solution into single-use portions and store at -20°C or below to maintain stability. Avoid repeated freeze-thaw cycles to preserve peptide integrity.

CYCLE/STACKING

In pulmonary and respiratory research, Chonluten may be combined with other compounds to investigate synergistic effects, complementary protective mechanisms, or multi-organ approaches to systemic health. Researchers might examine Chonluten alongside:

• BPC 157 5 mg - For research on combined tissue repair mechanisms in pulmonary and gastrointestinal systems
• TB 500/BPC 157 10 mg - To study comprehensive tissue regeneration approaches across multiple organ systems
• GHK-Cu 50 mg - For investigations of combined antioxidant and tissue remodeling effects
• SS-31 50 mg - To research complementary approaches to mitochondrial protection in pulmonary tissue
• NAD+ 500 mg - For studies examining interactions between cellular energy metabolism and pulmonary function

Stacking strategies should be carefully designed with consideration of administration routes (systemic versus local), potential tissue-specific interactions, and the specific research endpoints. Researchers should include appropriate controls to distinguish compound-specific effects from vehicle or procedural effects, and consider Chonluten's tissue-specific nature when planning combination studies that may involve different target organs or administration methods.

POST CYCLE THERAPY

As a research peptide with tissue-specific regulatory effects rather than systemic hormonal modulation, Chonluten does not produce the classic hypothalamic-pituitary suppression associated with anabolic compounds. However, researchers conducting longitudinal studies should implement appropriate observation periods after discontinuation to monitor:

1. Persistence or regression of pulmonary functional improvements;
2. Long-term maintenance of epithelial integrity and antioxidant defenses;
3. Potential compensatory changes in endogenous tissue repair mechanisms;
4. Rebound effects on inflammatory markers or oxidative stress parameters.

For studies examining significant pulmonary effects, researchers might include gradual dose tapering rather than abrupt discontinuation to better understand maintenance requirements and potential regression patterns. No traditional SERM or AI-based post-cycle therapy is required or appropriate for Chonluten research, though monitoring of pulmonary function parameters during and after administration is recommended.

SIDE EFFECTS

RESEARCH OBSERVATIONS ONLY. In experimental models, Chonluten has demonstrated an excellent safety profile with minimal observed adverse effects at research-relevant doses. Unlike systemically acting compounds, its tissue-specific nature minimizes off-target effects. The most commonly reported effects in research settings are mild, transient reactions at injection sites when administered parenterally. When administered via inhalation routes, some studies have reported minor, transient coughing or bronchial irritation that typically resolves within minutes. No evidence of systemic toxicity, organ damage, or carcinogenicity has been reported at research-relevant doses. The peptide's natural amino acid composition and tissue-specific mechanism contribute to its favorable safety profile in research settings. Importantly, Chonluten does not appear to produce hormonal side effects, metabolic disturbances, or cardiovascular changes at typical research concentrations.

CONTRAINDICATIONS

Chonluten is contraindicated for human consumption. For research purposes, experimental designs involving models with active pulmonary infections, severe respiratory distress, or acute lung injury should proceed with caution and appropriate veterinary monitoring. Researchers should exercise particular care when administering via inhalation routes to models with pre-existing bronchial hyperreactivity or severe airway obstruction. Studies involving pregnant animal models require special consideration and appropriate ethical approvals due to the peptide's potential effects on developing pulmonary tissue. Models with specific genetic alterations in pulmonary development or repair pathways may provide particularly interesting research opportunities but require careful experimental design and interpretation.

OVERDOSE

In research settings, doses significantly exceeding typical experimental ranges have shown minimal acute toxicity in animal models, reflecting the peptide's favorable safety profile and tissue-specific mechanism. However, extreme overdose via inhalation routes could theoretically cause bronchial irritation or transient respiratory discomfort. With parenteral administration, very high doses might produce mild, transient systemic effects. Researchers should establish careful dose-response relationships and have appropriate monitoring in place for high-dose studies, particularly when utilizing inhalation administration methods. No specific antidote exists for Chonluten overdose; management would involve supportive care appropriate to the experimental system and observed effects, with particular attention to respiratory parameters if inhalation routes are used at excessive doses.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE

Chonluten is for laboratory research use only by qualified professionals. Researchers should:

1. Consider the peptide's tissue-specific nature when selecting administration routes and designing experimental protocols;
2. Use appropriate administration techniques for the chosen route (subcutaneous, inhalation, etc.) with careful attention to aseptic procedure;
3. Monitor respiratory parameters in animal models, especially when using inhalation administration or studying pulmonary effects;
4. Consider potential differences in pulmonary responses based on species, age, and baseline pulmonary health;
5. Maintain strict aseptic technique during reconstitution and administration to prevent contamination, particularly critical for inhalation preparations;
6. Store both lyophilized and reconstituted material at recommended temperatures protected from light;
7. Design experiments with appropriate controls including vehicle administration and baseline pulmonary function measurements;
8. Consider potential interactions with other experimental manipulations that affect respiratory function, inflammation, or oxidative stress.

INTERACTIONS WITH OTHER DRUGS

In research models, Chonluten may interact with other compounds affecting pulmonary function, inflammatory responses, or oxidative stress pathways. According to research in European Respiratory Journal, pulmonary-targeted peptides may interact with:

1. Bronchodilators which could modulate airway responses;
2. Anti-inflammatory agents with potential additive or synergistic effects on pulmonary inflammation;
3. Antioxidants that may complement Chonluten's oxidative stress modulation;
4. Other tissue repair compounds with potential synergistic effects on regeneration;
5. Environmental toxins being studied for protective effects.

Researchers should review literature on pulmonary pharmacology and tissue-specific peptide regulation when designing combination studies to anticipate potential interactions and optimize experimental design.

PRESENTATION, PACKAGING

Each package contains one 2 mL amber glass vial with 20 mg of Chonluten as lyophilized powder. The vial is sealed with a bromobutyl rubber stopper (compatible with peptide stability) and aluminum overseal to maintain sterility and prevent moisture ingress. Peptide Hubs packages each vial in individual protective boxes with desiccant packs, and light-blocking materials. Labels include product name, batch number, manufacturing date, expiration date (typically 24 months from manufacture when stored properly), peptide content verification, purity certification, and "For Research Use Only" designation in compliance with research chemical standards. The 20 mg concentration provides flexibility for various research protocols including inhalation studies that may require higher total peptide quantities.

STORAGE

Store unopened vials at -20°C or below in original packaging protected from light. Lyophilized Chonluten remains stable for 24 months when stored frozen at -20°C or colder. For short-term use (within 30 days), refrigerated storage at 2-8°C is acceptable but not optimal for maximum long-term stability. Avoid temperature fluctuations and exposure to humidity, which can degrade peptide integrity through hydrolysis or aggregation. After reconstitution, aliquoted solutions should be stored at -20°C to -80°C and used within 30 days, avoiding repeated freeze-thaw cycles. For inhalation preparations, additional sterility precautions and shorter use timelines may be appropriate. Always inspect reconstituted solutions for clarity, color, and absence of particles or precipitation before research use.

DELIVERY TO THE USA

Peptide Hubs ships Chonluten 20 mg to research facilities in the United States. All packages are discreetly labeled for research use only with appropriate documentation consistent with research chemical distribution. Domestic reshipping services ensure reliable delivery to all 50 states with real-time tracking provided. Researchers should verify institutional policies regarding receipt of research peptides. Typical delivery requires 5-10 business days with expedited options available for time-sensitive research protocols.

LEGAL STATUS

Chonluten is sold exclusively as a research chemical for laboratory investigation. It is not approved by the FDA for human use, diagnosis, or treatment of any condition. In the United States, possession and use are legal for qualified researchers and institutions when used in compliance with applicable laws governing research chemicals. Purchasers must be at least 18 years old, represent legitimate research entities (universities, research institutes, pulmonary research laboratories), and agree to use the product exclusively for non-human research in controlled laboratory settings. Researchers must comply with all institutional, IACUC, state, and federal regulations governing animal research and chemical safety.

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Peptide Hubs, USA

EXTERNAL LINKS

• European Respiratory Journal: Pulmonary Regeneration - Scientific context for lung repair research
• PubChem: Bioregulator Compounds - Chemical information on tissue-specific peptides

PROFILE

• Chemical name: Lung tissue-derived peptide bioregulator (proprietary sequence)
• Chemical formula: Variable based on specific peptide composition
• Percentage of anabolic activity: Not applicable (tissue-specific regulator)
• Percentage of androgenic activity: 0% (no androgen receptor interaction)
• Active half life: Approximately 30-90 minutes in circulation (route dependent)
• Recommended dosage: Research doses typically 50-200 μg/kg in animal models
• Acne: None reported in research
• Bloating (water retention): None reported in research
• HBR: No hepatobiliary effects reported
• Hepatic toxicity: None observed in research models
• Aromatization: Not applicable (non-steroidal peptide)